Mazdutide (IBI362)
Metabolic Health · GLP-1/glucagon agonist (dual)
Tier B
Bottom line
Read Off Label grades Mazdutide (IBI362) as B (6.8/10) based on strong evidence, high benefit magnitude, and a med-risk safety profile.
Innovent Biologics; Chinese-approved for obesity and T2D in 2025.
Typical use: 4-9 mg SC weekly — Approved in China (June 2025) for chronic weight management; FDA filing TBD.
What this is
Innovent Biologics; Chinese-approved for obesity and T2D in 2025. GLORY-1 Phase 3 (China, n>600) showed -16.8% body weight at 32 weeks at 9 mg dose. Meaningful for biohacker readers because it reaches similar magnitude to tirzepatide and is already prescribed in China while Western markets wait. Particular interest for MASLD/NAFLD due to hepatic glucagon effects.
Mechanism
Dual GLP-1 and glucagon receptor agonist; glucagon arm increases hepatic fat oxidation and energy expenditure (similar mechanism to survodutide); developed by Innovent (China) under license from Lilly's OXM3
Dose & route
4-9 mg SC weekly
Citations
- https://doi.org/10.1016/j.metop.2026.100463
- https://pubmed.ncbi.nlm.nih.gov/40421736/
- https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01184-1/fulltext
- https://clinicaltrials.gov/study/NCT04904913
- https://pubmed.ncbi.nlm.nih.gov/39696983/
- https://clinicaltrials.gov/study/NCT04440345
- https://pubmed.ncbi.nlm.nih.gov/40479843/
- https://pubmed.ncbi.nlm.nih.gov/41743493/
- https://doi.org/10.3390/biomedicines14040909
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does Mazdutide (IBI362) work?
- Read Off Label rates the evidence for Mazdutide (IBI362) as Strong and the benefit magnitude as high, producing an overall grade of B (6.8/10). Innovent Biologics; Chinese-approved for obesity and T2D in 2025.
- Is Mazdutide (IBI362) safe?
- Mazdutide (IBI362) has a med risk profile in published human data. Legal status: Approved in China (June 2025) for chronic weight management; FDA filing TBD. This is not medical advice — see the disclaimer.
- What is the typical dose for Mazdutide (IBI362)?
- 4-9 mg SC weekly
- How does Mazdutide (IBI362) work?
- Dual GLP-1 and glucagon receptor agonist; glucagon arm increases hepatic fat oxidation and energy expenditure (similar mechanism to survodutide); developed by Innovent (China) under license from Lilly's OXM3
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.